World’s First Cancer-Killing Pill May be Available Within the Decade

Thanks to advancement made possible through the Human Genome Project, British researchers believe the world’s first cancer-killing pill may be on the horizon. According to the team’s timeline, such a pill may be available in as few as ten years.

The success of this future pill will work by exploiting a specific gene flaw that is present in cancer’s DNA. In lab tests, the British team was able to show that a mutation of specific cancer cells effectively blocked the disease’s ability to repair damaged genetic material. As such, a pill or injection could potentially be made that switches on this mutation and shuts down important repair mechanisms that cause the illness to grow uncontrollably.

Since such a drug would not affect the health of normal human cells, it is believed that treatment will not only be more effective, but also result in far fewer side effects.

A research team led by Professor Ghulam Mufti at Kings College London announced the findings on October 24th. Mufti summed up the findings by saying, “The genetics of cancers are being rapidly unraveled. We are soon going to have a library of what genetic abnormalities lead to which cancers. If these are specific, we can target these abnormalities using new treatments.”

Many researchers not affiliated with the study agree that all cancers are moving towards a targeted treatment process. Thanks in large part to the Human Genome Project, various research teams are now identifying potential genetic markers that may eventually lead to a cure for cancer.

One of the first of such drugs is currently being tested at the Breakthrough Breast Cancer Research Centre in London. This drug works in exactly the same manner as described by Mulfti – by altering a tumor’s cells so they cannot successfully repair DNA properly.

In early trials, the research team was able to show that breast cancer cells are killed while healthy cells are largely unaffected. The team also notes a complete lack of noticeable side effects.

Similar methods are also currently in the works for curing such illnesses as cystic fibrosis. Current medical trials that utilize gene therapy could lead to an effective cystic fibrosis treatment in as little as five years.

Sources:
http://www.express.co.uk/posts/view/207376/New-drugs-to-target-cancer
http://www.dailymail.co.uk/health/article-1323481/Cancer-killing-pill-exploits-flaw-diseases-DNA-close-development.html

New Gene Set Discovery Improves Targeted Treatment for Lung Cancer

A specific genetic signature has been linked to a high risk for recurrence of non-small cell lung caner following surgery, according to a team of researchers led by pathologist Dr. Ming Tsao. The discovery provides an avenue for identifying high-risk patients who may benefit from chemotherapy treatments once surgical removal of the tumor has occurred.

Previous studies have shown that post-surgical chemotherapy does not necessarily improve a lung cancer patient’s survival rate. Thanks to the newly identified biomarker, Tsao and his colleagues believe doctors can now identify which patients are most likely to benefit from additional chemotherapy, while sparing low-risk candidates from “the potentially debilitating side effects of this treatment.”

The study builds on a previous research study (dubbed JBR.10) conducted by the National Cancer Institute of Canada (NCIC) that concluded non-small cell lung cancer patients enjoyed improved survival outcomes with the help of chemotherapy drugs such as vinorelbine and cisplatin following surgery.

To come to their conclusions, Tsao and team reviewed the genetic data of 133 patients who took part in the 2005 JBR.10 research study. Through this analysis, the team was able to identify 15 genes that correlated to a high recurrence of cancer in cases where chemotherapy was not administered following surgery.

A randomized review of the JBR.10 results also allowed researchers to effectively “predict” which patients eventually experienced the most benefit from chemotherapy following surgery. The research indicates that both stage-I and stage-II lung cancer patients may benefit from chemotherapy following surgery.

The study was funded in part by the NCIC and U.S. National Cancer Institute. Research was performed in conjunction with researchers from the Princess Margaret Hospital Cancer Program and Ontario Cancer Institute.

 

Sources: http://www.newswise.com/articles/view/568122

http://topnews.co.uk/212581-gene-responsible-recurrence-cancer-among-patients

Anemia Drugs May Decrease Survival Time Among Cancer Patients

Doctors need to exhibit extreme caution before prescribing a class of anemia drugs known as erythropoeisis-stimulating agents (ESAs) to cancer patients, according to an updated guideline endorsed by the American Society of Hematology (ASH) and American Society of Clinical Oncology (ASCO).

Anemia is a fairly common side effect of chemotherapy. As a result, ESAs such as Procrit, Epogen and Arenesp are frequently prescribed to stimulate the production of additional red blood cells. While such medications are typically preferred over the alternative of blood transfusions, experts warn that such drugs have been linked to reduced survival times of cancer patients. An increased risk of internal blood clotting has also been noted.

According to the new guidelines, physicians are urged not to recommend ESAs for any cancer patient who is currently not undergoing chemotherapy (with the exception of patients with myelodysplastic syndrome). For patients dealing with chemotherapy, new guidelines suggest physicians should discuss the many benefits and risks of ESAs directly with each patient. When discussing these risks, it is also important to discuss the alternative of blood transfusions and how this alternative may affect quality of life.

These updated recommendations are based on the analysis of a variety of information sources. These sources include analysis of published clinical trials, various medical literature and reviews of individual patient data.

Further recommendations for dosage levels, thresholds for initiation and modification of ESAs are also detailed in the new guidelines. According to ASH member Samuel Silver, MD, “These are issues that confront practicing hematologists and oncologists on a daily basis, and we hope that these evidence-based recommendations will influence practice standards and result in better care for patients.”

Complete data related to the revised guidelines can be found at the following website:
http://jco.ascopubs.org/content/early/2010/10/25/JCO.2010.29.2201.abstract

Complete guidelines will also be published in the November 18th issue of Blood and the November 20th issue of the Journal of Clinical Oncology.

Sources:
http://www.prnewswire.com/news-releases/new-guideline-from-ash-and-asco-recommends-caution-regarding-esa-use-in-cancer-patients-105765143.html
http://health.usnews.com/health-news/managing-your-healthcare/cancer/articles/2010/10/26/use-anemia-drugs-for-cancer-patients-with-caution-experts-say.html

Blocking “Rogue Gene” May Prevent Cancer Spreading

Scientists at the University of East Anglia in England have reportedly discovered a “rogue gene” that can lead to the spread of cancer throughout the body.  The gene, labeled WWP2, attacks proteins in healthy cells that typically prevent the spread of cancer from one area of the body to another.  The researchers found that the WWP2 gene is often present in late-stage cancer patients as the disease moves to different organs, a process known as metastasis.

Metastasis often occurs in the late stages of the disease.  Cancer cells often spread through either the bloodstream or the lymph system and attack other organs.  In many cases, the metastasized tumors are the ones attributable for many fatalities, rather than the tumors at the original site.  The ability to prevent or forestall the metastatic process has long been considered an important factor in treating many forms of cancer.

Many types of cancer, including breast and colon cancers, are often aggressive and spread quickly throughout the body.  The research team also determined that the development of chemotherapy drugs that can target the WWP2 gene might interrupt the metastasis process.  The healthy cells, protected from the effects of WWP2, could fight off the cancerous mutations and prevent the spread of most types of cancers to other organs.

Dr. Andrew Chantry, one of the researchers who conducted the study, said that the work involved in creating such a drug “is a difficult but not impossible task”.  He also said that the biggest challenge would be to develop a drug that will attack the WWP2 gene within the cancer cells and stimulate the production of anti-cancer proteins.

Dr. Surinder Soond, another researcher on the study, said that the results showed “a novel and exciting approach” in the treatment of highly aggressive forms of cancer.  He also told reporters that the process “holds great potential” for preventing the spread of the disease.

Dr. Kat Arney, an official with the British agency Cancer Research UK, said that the WWP2 discovery “adds one more to this ever-growing list” of genes understood in the spread of cancer.  She said that the East Anglia study was helpful in learning more about the process behind how cancer spreads throughout the body, but that any potential applications of the discovery are ‘still at the laboratory stage”.

The discovery of the WWP2 gene has led to speculation that a new class of chemotherapy drugs could come about within the next ten years.  The anti-WWP2 drugs could prevent the spread of cancer to more susceptible organs, such as the heart or brain, while traditional chemotherapy routines or surgical procedures would still be used to attack the primary cancer site.

Sources:
http://www.bbc.co.uk/news/health-12254242
http://www.bloomberg.com/news/2011-01-24/blocking-rogue-gene-could-stop-spread-of-cancer-u-k-researchers-find.html
http://www.reuters.com/article/idUSLDE70J16V20110124

Scientists Fight Cancer With Cancer

Scientists at the Rogosin Institute in New York have found a new weapon in the fight against cancer: beads made from mouse cancer cells.  Researchers created the beads by removing cancer cells from mice and coating them in agarose, a sugar derived from seaweed.  In previous tests on animals, the study found that the beads significantly reduced the size of the surrounding tumors.

The beads start as a mixture of agarose and kidney cancer cells from mice.  The next step is to cover the mixture in another layer of agarose, creating the coating for the bead.  After three to ten days, almost all of the kidney cancer cells die off.  The remaining cells resemble cancer “stem cells” and begin to reproduce inside the bead.

As the stem cells divide and refill the bead’s interior, they emit proteins that other nearby cancer cells use as a signal.  The process essentially “tricks” cancer cells into believing that more cancer cells are nearby and that the existing cancer cells must stop growing.  In most cases, the tumors can stagnate, shrink, or die off entirely.

The process of testing the method on humans has already begun.  At least thirty cancer patients have been implanted with the beads, with more test subjects expected to join the study pending the early results.  The patients in the study have some of the most aggressive forms of cancer, including colon, pancreatic and prostate cancers, in the advanced stages of the disease.  The research team hopes to release the results from the small-scale study by the end of the year.

Dr. Howard Parnes, a researcher with the National Cancer Institute, called the efforts at Rogosin “a completely novel way” of looking at cancer treatment methods.  He said that the methods of moving mouse cancer cells into humans has yet to show any evidence of creating any ill effects on patients.  Dr. Parnes mentioned that the study showed a “remarkable proof of principle” that the genetic structure of cancer cells in one animal could be used as an effective treatment in another species.

Dr. Daniel Petrylak, director of the prostate-cancer program at Columbia University Medical Center, said that the results from the Rogosin study appear to be “very compelling”.  Dr. Petrylak said that he would soon select patients to take part in the next phase of the study.  Prostate cancer is often very aggressive and spreads quickly throughout the body, thus prostate cancer patients would be suitable candidates for further testing.

Dr. Barry Smith, director of the Rogosin Institute, said that the team’s results with lab mice were promising.  The study showed that mice treated with the beads showed a reduction in tumor size of up to sixty percent within a month of the procedure.  The group also treated eleven dogs with prostate cancer using the beads.  The dogs that received the beads lived an average of nearly six months, with one dog surviving for almost two years, compared with a typical survival time of less than two months for untreated dogs.

Sources:
http://online.wsj.com/article/SB10001424052748703555804576102081795100672.html
http://www.wtma.com/rssItem.asp?feedid=116&itemid=29625523
http://www.myfoxny.com/dpps/news/scientists-try-to-fight-cancer-with-cancer-dpgonc-20110125-gc_11580315

New Blood Test Could Improve Diagnosis and Treatment of Cancer

New blood test technology has been developed that is sensitive enough to detect cancer cells, according to researchers at Massachusetts General Hospital (MGH) and Veridex (a division of Johnson & Johnson).

A press release published by Johnson & Johnson suggests the technology, which is currently in development for commercial use, “will enable [circulating tumor cells] to be used both by oncologists as a diagnostic tool for personalizing patient care, as well as by researchers to accelerate and improve the process of drug discovery and development.”

A prototype of the technology has previously been able to successfully identify a variety of cancer cells in the blood (such as breast cancer, lung cancer and prostate cancer). The device is similar in size to a business card and makes use of a microfluidics chip to sift through blood samples and identify any signs of cancer.

Each microfluidics chip contains tens of thousands miniscule posts that are encased with a binding molecule. Different posts contain a different protein that is identified with different types of cancer. As such, if tumor cells are present in the blood sample, then they will stick to those posts that contain the matching binding protein. Based on this information, an identification of cancer can quickly be made.

Physicians and researchers are hopeful that the technology will not only ease diagnosis, but also assist in developing improved treatment regimens. This may be accomplished by routinely monitoring cancer cell counts to determine if a current treatment is offering positive effects. Additionally, the level of precision provided by the technology allows doctors to learn whether or not a specific tumor contains common genetic mutations that may warrant alternative treatment methods.

Though the current estimated cost of production is fairly expensive (each chip costs around $500), researchers are hopeful that the technology will one day be available on a global scale.

Ideally, the new blood tests will take a lot of the guesswork out of selecting a cancer therapy. According to Dr. Peter Ravdin, director of the Comprehensive Breast Health Center at the University of Texas Cancer Therapy & Research Center, current protocol requires doctors to “wait about three months and take an x-ray to see if the tumor has gotten smaller” once a treatment has been implemented.

With the help of Johnson & Johnson’s new technology, this wait-and-see timeline has the potential to be dramatically reduced.

Resources:
http://www.kens5.com/news/New-cancer-blood-test-could-revolutionize-treatment-112819334.html
http://www.technologyreview.com/blog/editors/26218/?nlid=3959

Hormone Receptor Identified as Potential Target for Cancer Treatment

At least 11 common cancers may be partially spurred by the presence of the follicle stimulating hormone (FSH), according to research conducted at the Mount Sinai School of Medicine and France’s National Institute of Health and Medical Research.

The findings suggest that cancer treatments that target FSH within cancerous tumors may serve as a viable method for both detecting early signs of cancer and treating the illness.

FSH is a receptor that is normally present within the blood vessels of reproductive organs. In woman, it contributes to the growth of ovarian follicles and production of estrogen. In men, the hormone assists in the production of spermatozoa.

Among organs outside the reproductive system, FSH is typically absent. However, analysis conducted by the Mount Sinai team reveals that FSH also pops up in blood vessels of certain types of cancer. The 11 cancer types linked to FSH include:

• Breast cancer
• Prostate cancer
• Colon cancer
• Pancreatic cancer
• Bladder cancer
• Kidney cancer
• Lung cancer
• Liver cancer
• Stomach cancer
• Testicular cancer
• Ovarian cancer

Interestingly, the presence of FSH was identified across all 11 cancers regardless of stage of the tumor. This fact indicates that FSH serves as a biomarker that can be used to facilitate early diagnosis.

According to the study’s lead researcher, Aurelian Radu, “This new tumor marker may be used to improve cancer detection. Tumor imaging agents that bind to the new marker could be injected in the vasculature and would make visible early tumors located anywhere in the body,” said Aurelian Radu of Mount Sinai, the study’s lead author.

These findings are based on research that examined biopsies of more than 1,300 cancer patients.

Beyond early detection, Radu and colleagues are hopeful that FSH can also be used as a successful target for treatment. Since the receptor is linked to growth of tumor blood cells, treatments targeting FSH may assist in:

• Blocking the formation of new blood vessels
• Inhibiting blood flow to tumors via coagulation
• Destroying existing tumor blood vessels

In all three cases, the desired outcome is a reduction of oxygen flow to the cancerous tumor. Ultimately, this outcome could result in reduced growth, shrinkage or altogether elimination of a tumor.

One major advantage of using FSH as a target for cancer treatment is that it is absent in most normal tissues. This means that FSH-related drugs may result in fewer side effects than current chemotherapy treatments.

Before treatment avenues that relate to FSH production can begin, the research team concedes that additional research is needed. Additionally, the team reiterates the need to search for the role of FSH beyond the 11 cancers already studied.

The Mount Sinai research was published in the October 21 issue of the New England Journal of Medicine.

Sources:
http://www.google.com/hostednews/afp/article/ALeqM5jehv-SS4E4K3anFw7-Qe3gFUl53A?docId=CNG.be1430cf7ec438b63479d0e3742332c8.921
http://www.eurekalert.org/pub_releases/2010-10/ind-cdo102010.php
http://sify.com/news/potential-therapeutic-target-across-a-range-of-cancer-types-found-news-international-kkvn4fgafcf.html
http://www.businessweek.com/lifestyle/content/healthday/644667.html

Blue Light Special: Killing Cancer With “Light Activation”

A new platinum-based compound that is activated by blue light offers a cancer-killing potency that is up to 80 times higher than that of current platinum-based anti-cancer drugs, according to research led by the University of Warwick.

Working in conjunction with researchers at Ninewells Hospital Dundee and the University of Edinburgh, the Warwick team hopes the new compound will improve cancer treatment effectiveness for a wide variety of cancers. According to Professor Peter Sadler, University of Warwick Department of Chemistry:

“This compound could have a significant impact on the effectiveness of future cancer treatments. Light activation provides this compound’s massive toxic power and also allows treatment to be targeted much more accurately against cancer cells.”

This assertion is backed up by initial tests performed at Ninewells Hospital Dundee. Here, a team tested the effectiveness of the new compound on killing cultivated esophageal cancer cells. The results of these studies were encouraging, with 50 percent of all cancer cells killed by a small concentration of 8.4 micro moles per liter of the compound.

Additional research for the compound is set to begin on ovarian and liver cancer cells.

Previous platinum-based compounds have been engineered to react to ultraviolet light. However, the narrow wavelength of ultraviolet rays has limited its real-world potential. Since the new compound reacts directly with visible blue light (as well as green light), it is expected to deliver a broader range of applications.

Researchers also report that the new compound is stable and easily administered. Additionally, it is water soluble, meaning that it simply dissolves and flushes from the body following treatment.

Peter Sadler explains that “light activation generates a powerful cytotoxic compound that has proven to be significantly more effective than treatments such as cisplatin.” As a result, the team has hopes that the new compound will offer effective treatment options for cancer types that do not traditionally respond well to platinum-based chemotherapy.

Source:
http://www.news-medical.net/news/20101210/Researchers-find-new-light-activated-platinum-based-compound-to-kill-cancer-cells.aspx

Could RNA Interference be the Key to Shutting Down Cancer?

Each individual cancer cell displays a multitude of genetic mutations. Among the hundreds of these potentially hazardous mutations, scientists believe that the alteration of one to twelve could be enough to render a caner cell impotent and effectively shut it down within the body. The method currently being proposed to achieve this potentially landmark procedure is known as RNA interference.

RNA interference is a naturally occurring cellular phenomenon. In normal cell division, DNA must be transported from the nucleus to the ribosomes. However, RNA can disrupt this path by intercepting small snippets of genetic material en route. This unique type of RNA is specifically referred to as short interfering RNA (siRNA).

As Dr. Daniel Anderson of the David H. Koch Institute for Integrative Cancer Research at MIT explains, this method of interference “offers the potential to turn off essentially any gene in the cell.”

To bring this new theory of cancer treatment into practice, two factors must be addressed. The first is identifying which specific cancer mutations to target for interference. On the top of the list for researchers are those genes that cause cancer cells to divide and replicate quickly. In some cases, such genes have already been identified. However, it should be noted that different kinds of cancer might require different targets for RNA interference.

The second factor that needs to be addressed is finding a way to safely deliver siRNA to cancer cells without overly affecting healthy tissues. According to Steven Dowdy of the University of California, San Diego, delivery of this siRNA is the “number one hurdle” associated with RNA interference treatment.

Presently, the leading candidate for delivery of siRNA is via a fatty molecule called a lipidoid. With RNAi hidden within the lipidoid, the molecule can slip into a cell’s membrane and allow the RNA to go to work. Researchers at MIT have already shown that such a process can be effective in shutting off specific genes within the livers of mice. They have also made progress in reducing ovarian cancer tumor growth in mice via the procedure.

A number of additional steps are required before lipidoid transmission is ready for clinical trials. Most notably, is the fact that lipidoid molecules are fairly large in comparison to RNA data. As a result, the transmission could be hindered.

Another issue is the potential for the lipidoid to enter a normal cell. If such a scenario occurs, the DNA of a healthy cell could be abnormally damaged. To address this issue, scientists are toying with the idea of engineering lipidoids that are peppered with specific proteins. These proteins serve as a homing device of sorts by being drawn to binding proteins present on the exterior of cancer cells.

Currently, experts on the subject such as Dr. Dowdy believe patient-specific RNA interference could be readily available within ten to 20 years. As he sees it, future patients will have their tumors genetically sequenced to discover which cancer-causing genes have been activated. Once this information is known, a specific siRNA treatment can be implemented to effectively shut off the cancer’s ability to proliferate.

Source:
http://web.mit.edu/newsoffice/2010/targeting-cancer2-1116.html

50 Percent of Cancer Patients May Benefit From Oxygen-Carrying Compounds

Engineered proteins that help carry oxygen to cancer tumors may improve the odds of successful treatment for approximately half of all cancer patients. Scientists have long known that low levels of oxygen are a main source of a tumor’s resistance to radiation.

It is estimated that 50 percent of all cancer patients have tumors that exhibit insufficient oxygen levels (a state referred to as hypoxia). Now, a small startup based out of San Francisco known as Omniox is working to improve the effectiveness of current radiation treatments through the use of oxygen-carrying compounds.

Previous studies suggest that the vast majority of cancer tumors exhibit hypoxic regions. These oxygen-starved regions occur due to the rapid growth of tumor cells. As the tumor grows, it requires higher and higher levels of oxygen-rich blood to properly feed the growth of cells. To accomplish this, the tumor stimulates the growth of new blood vessels.

However, the growth of new blood vessels often has difficulty keeping up with the growth of the tumor. Such a fact reduces the effectiveness of radiation – a treatment option that relies heavily on the flow of oxygen.

Radiation therapy works by generating free radicals within the body that damage and kill tumor cells. Since free radicals require oxygen to survive, a hypoxic region often receives insufficient damage to completely kill off the tumor.

The issue of improving oxygen flow to tumors has been studied since the 1950s. Unfortunately, a variety of attempted solutions have proven unsuccessful. Omniox hopes to reverse this trend with the introduction of oxygen-carrying proteins.

These proteins have been augmented to cling to oxygen molecules and hold onto them until they have arrived inside hypoxic tissue. These proteins differ from previous oxygen-carrying options in that the proteins are not based on hemoglobin. Hemoglobin has previously been identified as unsuccessful because nitric oxide (an oxygen-killing material) also clings to such molecules.

Previous studies have shown that Onniox’s proteins effectively accumulate in the tumors of living animals and serve to improve oxygen levels in hypoxic regions.

The National Cancer Institute is working in conjunction with Omniox to further develop and research the oxygen-carrying proteins. The NCI recently awarded the startup with $3 million in funding.

Source:
http://www.technologyreview.com/biomedicine/26772/page2/